www.iosrjen.org
IOSR Journal of Engineering (IOSRJEN) ISSN (e): 2250-3021, ISSN (p): 2278-8719 Vol. 4, Issue 4 (April. 2014), ||V7|| PP 23-27
Feature Extraction for Alzheimer’s Disease Sangam Mhatre (Department of Instrumentation Engineering, R.A.I.T, Navi Mumbai) Sangam9838@gmail.com
Abstract: - Alzheimers disease (AD) is a progressive and degenerative disease that affects brain cells, and its early diagnosis has been essential for appropriate intervention by health professionals. Noninvasive in vivo neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) are commonly used to diagnose and monitor the progression of the disease and the effect of treatment. In this regard, the problem of developing computer aided diagnosis (CAD) tools to distinguish images with AD from those of normal brains. Computer Aided Diagnosis is applied to the field of medical image diagnosis. It can improve the accuracy and accordance of the diagnosis result. According to the analysis of the features of the images information, we get the result. If the features extracted are carefully chosen it is expected that the features set will extract the relevant information from the input data in order to perform the desired task using this reduced representation instead of the full size input. The vast majority of 3D brain image-based computer aided diagnosis methods implemented so far relied simply on voxel intensity, as feature. Classification is accomplished through Support Vector Machines, after an automatic feature selection step.
Keywords: - Alzheimer’s disease, feature extraction, feature transformation, voxel intensity
I.
INTRODUCTION
Alzheimer’s disease (AD), named after the German physician Alois Alzheimer, is a condition defined by progressive dementia and the abundant presence in the brain of characteristic neuropathological structures. The earliest symptom is generally memory loss, followed by further functional and cognitive decline, such that patients become gradually less able to perform even basic tasks. There is currently no disease-modifying therapy for AD however, symptomatic treatments can help patients to maintain mental function and manage the behavioural symptoms. Ongoing clinical trials are focused on the development of new treatments, including those aimed at lowering the risk of developing the disease or delaying its onset and progression . As illustrated in Figure 1.1, changes associated with AD are thought to start occurring many years before the onset of clinical symptoms. Any disease-modifying or causal therapy would therefore likely be of greatest benefit to asymptomatic individuals at high risk of developing AD, so-called pre-symptomatic patients. A diagnosis of AD is made according to consensus such as the NINCDS-ADRDA Alzheimers Criteria , which provide guidelines for the classification of patients as having definite, probable, or possible AD. A diagnosis of definite AD requires that neuropathological findings be confirmed by a direct analysis of brain tissue samples, which may be obtained either at autopsy or from a brain biopsy. A delay of one year in both disease onset and progression would reduce the number of AD cases in 2050 by an estimated 10% . The early identification of presymptomatic patients is therefore important to allow the recruitment of appropriate participants for clinical trials. If a successful disease-modifying therapy for AD were to be developed, early identification would become even more important to allow targeting of patients for whom the treatment may be most effective.
Figure 1.1: An illustrative timeline of AD progression.
International organization of Scientific Research
23 | P a g e